FY2024 EPS Estimates for Achilles Therapeutics plc (NASDAQ:ACHL) Boosted by Chardan Capital theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Chardan Capital restated their buy rating on shares of Achilles Therapeutics (NASDAQ:ACHL – Free Report) in a research note published on Monday morning, Benzinga reports. They currently have a $11.00 target price on the stock. Chardan Capital also issued estimates for Achilles Therapeutics’ FY2024 earnings at ($1.58) EPS. Achilles Therapeutics Trading Up 2.0 % NASDAQ […]
Achilles Therapeutics plc (NASDAQ:ACHL – Get Rating) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 14,800 shares, a growth of 114.5% from the April 30th total of 6,900 shares. Approximately 0.0% of the company’s shares are sold short. Based […]
Achilles Therapeutics plc (NASDAQ:ACHL – Get Rating) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 13,000 shares, a growth of 106.3% from the March 15th total of 6,300 shares. Based on an average daily volume of 258,600 shares, the short-interest ratio is […]